GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (TSX:APS) » Definitions » Price-to-Owner-Earnings

Aptose Biosciences (TSX:APS) Price-to-Owner-Earnings : (As of May. 23, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Aptose Biosciences Price-to-Owner-Earnings?

As of today (2025-05-23), Aptose Biosciences's share price is C$2.45. Aptose Biosciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Aptose Biosciences's Price-to-Owner-Earnings or its related term are showing as below:


TSX:APS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.53
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-23), Aptose Biosciences's share price is C$2.45. Aptose Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was C$-37.59. Therefore, Aptose Biosciences's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-23), Aptose Biosciences's share price is C$2.45. Aptose Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was C$-38.07. Therefore, Aptose Biosciences's PE Ratio without NRI for today is At Loss.


Aptose Biosciences Price-to-Owner-Earnings Historical Data

The historical data trend for Aptose Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Price-to-Owner-Earnings Chart

Aptose Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aptose Biosciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aptose Biosciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Aptose Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptose Biosciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptose Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Aptose Biosciences's Price-to-Owner-Earnings falls into.


;
;

Aptose Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Aptose Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.45/-17.46
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptose Biosciences  (TSX:APS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Aptose Biosciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptose Biosciences Business Description

Traded in Other Exchanges
Address
66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, ON, CAN, M5K 1E6
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Executives
Bernd Robert Seizinger Director
William Glenn Rice Director, Senior Officer
Erich Platzer Director
Rafael Bejar Senior Officer
Warren Whitehead Director
Gregory Kwok Lee Chow Senior Officer
Jotin Marango Senior Officer

Aptose Biosciences Headlines

No Headlines